15 min listen
Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targe…
Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targe…
ratings:
Length:
17 minutes
Released:
Sep 19, 2023
Format:
Podcast episode
Description
Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.
Released:
Sep 19, 2023
Format:
Podcast episode
Titles in the series (88)
George Kassianos, CBE, MD (Hons), FRCGP - A Vaccinator’s Guide to Viral Vector–Based COVID-19 Vaccines: Please visit answersincme.com/KAG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology